Companies and Deals | Danish pharmaceutical company | Eli Lilly & Co | Markets | Novo Nordisk | Novo Nordisk A/S shares
Novo Nordisk is trading as if obesity drug craze never happened
The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.